cilnidipine
Sign in to saveAlso known as FRC-8653, (+-)-(E)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Cilnidipine is a calcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Nepal, and Korea for hypertension.
Research
355 papers- Cilnidipine, a Dual L/N-type Ca(2+) Channel Blocker in Hypertension Management: A Review.The Journal of the Association of Physicians of India · 2024
- Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials.Cureus · 2021
- Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.Cardiovascular therapeutics · 2009
- The Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement: National Consensus Group Comprises Cardiologists, Nephrologists, and Diabetologists from India in a National Meet at New Delhi held on 22(nd) May 2022.The Journal of the Association of Physicians of India · 2024
- An Investigative Review for Pharmaceutical Analysis of 1,4-Dihydropyridine-3,5-Dicarboxylic Acid Derivative: Cilnidipine.Critical reviews in analytical chemistry · 2021
via PubMed
~3 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- Side effects
- Brand names
- History
- References
- Further reading
Cilnidipine is a calcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Nepal, and Korea for hypertension.
It is a calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. Unlike other calcium antagonists, cilnidipine can act on the N-type calcium channel in addition to acting on the L-type calcium channel.
Excerpted from Wikipedia’s “cilnidipine” article, available under the CC BY-SA 4.0 licence.